Depressed patients and their physicians naturally expect that each new antidepressant that reaches the market will represent a conceptual and therapeutic advance over previous medications. We can determine how realistic this expectation may be if we review dispassionately the validity of the assumptions that underlie the development of new antidepressants and the data supporting their differential effectiveness.
No takes yet. Share an insight, caveat, or question.
Steven Dubovsky (2018) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: